Use of Dienogest or Gonadotropin Releasing Hormone Agonist with Add back Hormone Therapy in Longterm Endometriosis Medical Management

In: Open Access Journal of Gynecology · 2018 · vol. 3(1) · doi:10.23880/oajg-16000151 · W2892596676
article OA: diamond CC0 ⤵ 2 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-08

This review discusses the long-term use of dienogest or GnRH agonists with add-back therapy for endometriosis recurrence, focusing on adolescents and young adults.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Since endometriosis is a recurrent disease one needs longterm treatment for prevention of recurrence.2commonly used drugs for same are dienogest and gonadotropin releasing hormone agonists. There is not much experience with dienogest use, although enough experience exists regarding GnRH agonists. Important is to use add back hormone therapy with these agonists to prevent undesirable side effects. Rest selection of either of the drugs depends on cost, patient preference, drs experience, therapeutic effectiveness, tolerability and patients compliance expected. Thus we discuss the role of each agent in use for longterm endometriosis recurrence and in case of adolescents and patients presenting with endometriosis in young adults needing longterm therapy.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (2)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK